Results 151 to 160 of about 138,725 (257)

Bullous Central Serous Chorioretinopathy Associated With JAK Inhibitor Use. [PDF]

J Vitreoretin Dis
Apel W, Li Y.
europepmc   +1 more source

Targeting interferon responses in juvenile dermatomyositis: Siglec-1 as an in vitro biomarker for JAK inhibitor efficacy. [PDF]

Rheumatology (Oxford)
Veldkamp SR, Reugebrink M, Evers SW, Moreau TRJ, Bondet V, Armbrust W, van den Berg JM, Hissink Muller PCE, Kamphuis S, Schatorjé E, Delemarre EM, van der Kooi AJ, Bader-Meunier B, Duffy D, Rodero MP, Raaphorst J, van Royen-Kerkhof A, Jansen MHA, van Wijk F.   +18 more
europepmc   +1 more source

Narrow spectrum kinase inhibitors demonstrate promise for the treatment of dry eye disease and other ocular inflammatory disorders [PDF]

, 2018
Doughty, Michael, Foster, Martyn R., Fyfe, Matthew C.T., Hagan, Suzanne, Ofori-Frimpong, Boatemaa, Oliver, Katherine, Rowley, Adele, Sirohi, Sameer, Solanke, Yemisi, Taylor, Mike, Walshe, Claire A., Webber, Steve   +11 more
core   +1 more source

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012 [PDF]

, 2014
John T. Reilly, Mary Frances McMullin, Philip Beer, Nauman M. Butt, Eibhlin Conneally, Andrew Duncombe, Anthony R. Green, G. Mikhaeel, Maria Gilleece, Steven Knapper, Adam J. Mead, Ruben A. Mesa, Mallika Sekhar, Claire Harrison   +13 more
openalex   +1 more source

Towards New Strategies: Case Report and Review of the Literature-Effective Use of JAK Inhibitor Baricitinib in a 4-Year-Old Boy with Anti-MDA5 Antibody-Positive Juvenile Dermatomyositis. [PDF]

J Clin Med
Buzoianu O, Satirer Ö, Kuemmerle-Deschner JB, Reiser C.   +3 more
europepmc   +1 more source

Reversal of CD8 T-Cell–Mediated Mucocutaneous Graft-Versus-Host-Like Disease by the JAK Inhibitor Tofacitinib [PDF]

, 2013
Naoko Okiyama, Yasuko Furumoto, Vadim A. Villarroel, Jay T. Linton, Wanxia Li Tsai, Jan Gutermuth, Kamran Ghoreschi, Massimo Gadina, John J. O’Shea, Stephen I. Katz   +9 more
openalex   +1 more source

Protocol for transcriptomic and epigenomic analysis of JAK inhibitor sensitivity in IFN-γ-primed human macrophages using ATAC-seq and RNA-seq. [PDF]

STAR Protoc
Kwon G, Noh J, Lee J, Kang K, Kang K.
europepmc   +1 more source

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience. [PDF]

J Clin Med, 2023
Taylor PC, Laedermann C, Alten R, Feist E, Choy E, Haladyj E, De La Torre I, Richette P, Finckh A, Tanaka Y.   +9 more
europepmc   +1 more source

Radiological changes in STING-associated vasculopathy of infancy treated with a JAK inhibitor. [PDF]

Pediatr Int
Sato T, Nagatani Y, Hirota Y, Kunitsu T, Maruo Y.   +4 more
europepmc   +1 more source

306 Dual Therapy for Atopic Dermatitis: How Lebrikizumab and JAK inhibitors are used in Tandem for Treatment Resistant Cases [PDF]

Alexandra Nigro, Saakshi Khattri
openalex   +1 more source